Zinc supplement in acutely hospitalized older adults
Official title: ZOOM IN Study: Micronutrient Deficiencies and Effect of Zinc Supplementation on Inflammation and Occurrence of Infections in Older Medical Patients (ZOOM) - A Sub-study of a Cluster Randomized Trial
Run by Herlev Hospital · NCT07672132 · Data updated 2026-11-12
In people aged 65 and older who are acutely admitted to the hospital, taking 22 mg of zinc daily for 12 months is tested to see if it lowers inflammatory markers and improves health outcomes.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 65 Years and up |
| Sex | All |
| Enrollment | 220 (estimated) |
| Sponsor | Herlev Hospital Academic / other |
| Locations | 1 site (Herlev, Region Hovedstad) |
| Status | Recruiting |
| Started | June 2, 2026 |
| Main results expected | May 31, 2027 |
| Study ends | May 31, 2028 |
| Registry record updated | September 24, 2026 |
| Trial ID | NCT07672132 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 65 or older who are acutely admitted to Herlev Hospital and not taking more than 10 mg of zinc daily at baseline.
✕Probably not a fit
Patients who are unable to complete 12 months of follow-up or have conditions that contraindicate zinc supplementation may not experience benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study examines whether a daily 22 mg zinc supplement over 12 months can reduce inflammatory biomarkers in acutely hospitalized adults aged 65 and older. It also looks at whether zinc lowers self-reported infection symptoms, reduces readmissions and mortality, and improves quality of life and physical performance. The trial will monitor potential adverse events and compare albumin-corrected plasma zinc to ordinary plasma zinc as a measure of zinc status. Participants are recruited from Herlev Hospital, with specific inclusion and exclusion criteria to identify eligible older adults. The study seeks to determine safety, potential benefits, and the usefulness of zinc status testing methods in this population.
Why it matters
Potential benefit: If successful, zinc supplementation could reduce inflammation and improve health-related outcomes in older hospitalized patients.
How similar studies have gone: Previous work in older adults has explored zinc and inflammation with mixed results, making this study relevant for confirming potential benefits in an acutely hospitalized population.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * above 65 years old included in ZOOM out ( clinical trials no: NCT07367412) * admittet at the medical emergency department Herlev Hospital Exclusion Criteria: * Patients receiving zinc supplements (\>10 mg daily) at time of inclusion * Patients with terminal illness (life expectancy \< 6 months, estimated by Clinical Frailty Scale ≥8) * Patients receiving parenteral nutrition (partial or complete) * Patients treated with hemodialysis or peritoneal dialysis * Patients known with severe dementia * Patients who do not understand Danish and patients with temporary civil person registration numbers (CPR)
Where it's running
-
Herlev Hospital
Herlev, Region Hovedstad, Denmark Recruiting
Study contacts
- Study coordinator: Cecilia M Lund, MD, PhD
- Email: cecilia.margareta.lund.01@regionh.dk
- Phone: +4538686112
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Rituximab for treating immune-related side effects from checkpoint inhibitors
This small early-phase trial tests whether a single 100 mg dose of rituximab can help manage immune-related adverse events in adults with malignant melanoma who are on checkpoint inhibitors, alongside a tapering corticosteroid plan.
-
Group-based follow-up for women after obstetric anal sphincter injury
A group-based follow-up program is being tested to see if it can improve quality of life for women who had a tear at the anal sphincter after childbirth.
-
Neoadjuvant immunotherapy for high-risk eye melanoma
This trial tests whether giving nivolumab and ipilimumab before surgery is safe and feasible for adults with high-risk uveal melanoma.
-
Zinc supplementation in older medical patients to see if days alive and out of hospital improve
Giving 22 mg of zinc once daily for 12 months to older medical patients in the ED is being tested to see if it helps more days alive and out of the hospital compared with not giving zinc.
-
Endoscopic ultrasound-guided radiofrequency ablation for pancreatic and left adrenal lesions
This will try EUS-guided radiofrequency ablation to control symptoms and hormone-related problems in adults with small pancreatic neuroendocrine tumors (including insulinomas) or certain left adrenal adenomas.
-
Microbes linked to pancreatic cancer and early pancreatic lesions
This will see if microbes from the mouth, stool, and pancreas can help diagnose or predict outcomes for adults with suspected pancreatic lesions.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.